Results 11 to 20 of about 18,162 (243)

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

Lancet, The, 2007
Jose M Gatell, Adriano Lazzarin
exaly   +3 more sources

Eficacia y seguridad en condiciones clínicas reales del raltegravir en un hospital de referencia del seguro social peruano

Enfermería Global, 2021
Introducción: El Rategravir pertenece a los inhibidores de integrasas, quedando demostrado y aprobado por diversos ensayos clínicos como un potente antirretroviral seguro y eficaz para el tratamiento de pacientes infectados con el virus de ...
Elias Contreras-Calero, Marcos Saavedra-Velasco, Fernando Mendo-Urbina , Carlos Muñoz-Medina, J. Antonio Grandez-Urbina, Rafael Pichardo-Rodriguez   +5 more
doaj   +1 more source

Raltegravir in treatment naïve patients

European Journal of Medical Research, 2009
Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug resistant viruses.
Cossarini F, Castagna A, Lazzarin A
doaj   +1 more source

Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients

Cells, 2022
Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few studies focused on virus-targeted cells. We aimed our study
Gaurav Kumar, Jacqueline Cottalorda-Dufayard, Rodolphe Garraffo, Francine De Salvador-Guillouët, Eric Cua, Pierre-Marie Roger   +5 more
doaj   +1 more source

Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE-2 study. [PDF]

HIV Med
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Mussini C, Henegar C, Assoumou L, de Wit S, Johnson M, Quiros-Roldan E, Kenyon C, Deschanvres C, Zucman D, Post F, Movahedi R, Comi L, Fox J, Liegeon G, Martin C, Edwards J, Tiecco G, Delforge M, Ragone L, Jones B, van Wyk J, Aboud M, Fletcher C, Pozniak A, Vannappagari V.   +24 more
europepmc   +2 more sources

Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. [PDF]

, 2014
Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects.
Boger, M Sean, Currier, Judith S, Hulgan, Todd, Lake, Jordan E, Liao, Diana H, Mangili, Alexandra, McComsey, Grace A, McCreath, Heather, Milne, Ginger L, Sanchez, Stephanie C, Walmsley, Sharon L, Wanke, Christine A   +11 more
core   +3 more sources

Drug-drug interactions with raltegravir

European Journal of Medical Research, 2009
Objective To review all currently published drug-drug interaction studies with the HIV-integrase inhibitor raltegravir. Methods A PubMed search was conducted for all published reports up to August 1, 2009 as well as a review of updated European and US ...
Burger David M
doaj   +1 more source

Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen : a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from antiretroviral therapy-suppressed human immunodeficiency virus-infected individuals [PDF]

, 2018
Background: Optimization of combination antiretroviral therapy (cART) can impact the human immunodeficiency virus (HIV) reservoir. We evaluated the effect on the HIV reservoir in peripheral blood and ileum biopsies in patients switching from boosted ...
Blanco, Julià, Crespo, Manel, De Clercq, Laura, Gálvez, Cristina, Jimenez, Montse, Martinez-Picado, Javier, Moron-Lopez, Sara, Navarro, Jordi, Puertas, Maria C, Ribas, Bibiana Planas, Rutsaert, Sofie, Salgado, Maria, Torrella, Ariadna, Universitat Autònoma de Barcelona, Urrea, Víctor, Vandekerckhove, Linos   +15 more
core   +3 more sources

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N, Bourgi, Kassem, Crane, Heidi, Gange, Stephen J, Gill, John, Horberg, Michael A, Jenkins, Cathy A, Kirk, Gregory, Koethe, John R, Lake, Jordan, Li, Jun, Lima, Viviane D, Margolick, Joseph, Mathews, William C, Moore, Richard D, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Palella, Frank, Rabkin, Charles S, Rebeiro, Peter F, Silverberg, Michael, Sterling, Timothy R, Thorne, Jennifer, Willig, Amanda, Wong, Cherise   +23 more
core   +1 more source

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. [PDF]

, 2014
BackgroundDolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF).MethodsING116070 is an ongoing, single-arm, open-label ...
Chen, Shuguang, extended ING116070 study team, Letendre, Scott L, Mills, Anthony M, Min, Sherene S, Piscitelli, Stephen C, Song, Ivy H, Tashima, Karen T, Thomas, Deborah A   +8 more
core   +3 more sources